Hemangiosarcoma in Dogs - Symptoms, Diagnosis & Treatment

> Disclaimer: This article is intended for educational purposes only and does not constitute veterinary medical advice. Always consult a licensed veterinarian for diagnosis and treatment of your dog's health concerns.

---

What Is Hemangiosarcoma?

Hemangiosarcoma (HSA) is an aggressive, malignant cancer of the cells that line blood vessels (endothelial cells), meaning it can develop virtually anywhere in the body where blood vessels exist. It is one of the most devastating cancers diagnosed in dogs, accounting for approximately 5–7% of all canine tumors, and it is notorious for its ability to grow silently, spread rapidly, and cause life-threatening internal bleeding with little or no warning. Because tumors form within the vascular system itself, they are highly prone to rupture and metastasize through the bloodstream to distant organs.

The most common sites of origin are the spleen, the right atrium of the heart, and the skin or subcutaneous tissue. Less frequently, the liver, lungs, and musculoskeletal tissues are involved. When the primary tumor is located internally—particularly on the spleen or heart—owners often notice no clinical signs until the tumor ruptures and causes acute, massive hemorrhage, making early detection extremely difficult without routine screening.

---

Symptoms of Hemangiosarcoma in Dogs

Because hemangiosarcoma often grows silently, symptoms vary dramatically depending on tumor location and whether rupture has occurred. Recognizing even subtle early warning signs gives owners the best chance of intervention.

Early Signs

• Subtle, unexplained fatigue or reduced exercise tolerance
• Occasional episodes of weakness or brief collapse that seem to resolve on their own (often caused by minor internal bleeding that self-tamponades)
• Mild, intermittent abdominal distension or a "pot-bellied" appearance
• Pale or white gums (pallor) noticed occasionally after exertion
• Decreased appetite or mild weight loss over weeks
• A visible, raised lump under the skin (in cutaneous or subcutaneous forms), often appearing dark reddish-purple or flesh-colored
• Irregular heartbeat or heart murmur detected during a routine exam (cardiac HSA)

Progressive Symptoms

• Worsening abdominal swelling caused by internal bleeding into the abdomen (hemoabdomen)
• Increasing lethargy and reluctance to move
• Labored or rapid breathing (dyspnea), particularly with cardiac or pulmonary involvement
• Persistent pale or white-to-grey gums indicating anemia
• Rapid, weak pulse
• Distended jugular veins (with pericardial effusion from cardiac HSA)
• Progressive weight loss and muscle wasting (cachexia)
• Fluid accumulation around the heart (pericardial effusion) causing muffled heart sounds
• Neurological signs such as stumbling, head tilt, or seizures if metastasis reaches the brain

Emergency Signs

Seek immediate veterinary care if your dog shows any of the following:

• Sudden, severe collapse or inability to stand
• Extremely pale, white, or blue-tinged gums
• Rapid, labored, or gasping breathing
• Distended, tense abdomen that appears suddenly
• Signs of shock: rapid weak pulse, cold extremities, profound weakness
• Unresponsiveness or sudden loss of consciousness
• Acute seizures without prior history

---

What Causes Hemangiosarcoma in Dogs?

The precise cause of hemangiosarcoma is not fully understood, but research has identified several contributing factors:

• Genetic mutations: Somatic mutations in genes regulating vascular cell growth—including mutations in the TP53 tumor suppressor gene and PI3K/AKT signaling pathway—are frequently identified in canine HSA. These mutations cause endothelial cells to proliferate uncontrollably.
• Breed predisposition: Strong hereditary components exist, with certain breeds far more commonly affected (see below). This suggests inherited genetic vulnerabilities play a significant role.
• UV radiation (cutaneous form): Dogs with light-colored, thin coats and limited pigmentation in sparsely haired areas (groin, abdomen) are at higher risk for the dermal form of HSA due to chronic sun exposure.
• Age: Most affected dogs are middle-aged to older, typically between 8 and 13 years of age, suggesting that cumulative cellular damage over time contributes to tumor development.
• Sex: Some studies indicate intact males may have a slightly higher risk, though HSA affects both sexes. The impact of spay/neuter status on HSA risk remains an active area of research.
• Environmental and epigenetic factors: Chronic inflammation, immune dysregulation, and possible environmental carcinogen exposure are theorized contributors, though no single environmental toxin has been definitively linked to canine HSA.

Breeds Most at Risk

While hemangiosarcoma can occur in any breed, certain breeds are disproportionately affected, strongly suggesting a genetic basis:

| Breed | Relative Risk | |---|---| | Golden Retriever | Very high — estimated lifetime risk of 1 in 5 | | German Shepherd Dog | Very high | | Labrador Retriever | High | | Boxer | High | | Doberman Pinscher | High | | Flat-Coated Retriever | High | | Bernese Mountain Dog | Moderate-high | | Rottweiler | Moderate-high | | Skye Terrier | Moderate | | Portuguese Water Dog | Moderate |

Golden Retrievers and German Shepherds are the most commonly studied breeds. In Golden Retrievers, the Morris Animal Foundation's Golden Retriever Lifetime Study is actively investigating genetic and environmental factors contributing to cancer risk in this breed. The high prevalence in these breeds has driven significant research into early detection biomarkers and breed-specific genetic screening.

Mixed-breed dogs can also develop HSA, though generally at lower rates than the highest-risk purebreds.

---

How Hemangiosarcoma Is Diagnosed

Diagnosing hemangiosarcoma—especially before rupture—requires a systematic approach combining physical examination, laboratory work, and advanced imaging.

Step 1: Physical Examination

Your veterinarian will assess overall health, palpate the abdomen for masses or fluid, listen for cardiac abnormalities, and examine the skin for suspicious lesions. Pale gums or an enlarged spleen on palpation often prompt further workup.

Step 2: Complete Blood Count (CBC) and Chemistry Panel

• CBC frequently reveals anemia (often regenerative), thrombocytopenia (low platelets), and fragmented red blood cells (schistocytes) — hallmarks of HSA-related hemorrhage.
• Chemistry panel evaluates liver and kidney function, which may be affected by metastatic disease.
• Coagulation tests (PT/PTT) assess clotting ability, as disseminated intravascular coagulation (DIC) can complicate HSA.

Step 3: Abdominal and Thoracic Ultrasound

Ultrasound is the cornerstone of HSA detection. It can identify splenic or hepatic masses, free abdominal fluid (blood), and assess other organs for metastatic lesions. Thoracic X-rays evaluate for pulmonary metastasis.

Typical cost: $300–$600 for abdominal ultrasound; $150–$250 for chest X-rays.

Step 4: Echocardiogram

When cardiac HSA is suspected—or as part of a full staging workup—an echocardiogram evaluates the heart for masses and pericardial effusion.

Typical cost: $400–$800.

Step 5: CT Scan (Computed Tomography)

CT provides detailed three-dimensional imaging for surgical planning and accurate staging of metastatic spread to lymph nodes, lungs, and other organs. It is increasingly considered standard of care before surgery.

Typical cost: $1,500–$2,500.

Step 6: Histopathology

Definitive diagnosis requires microscopic examination of tumor tissue by a veterinary pathologist. Biopsy is typically obtained at the time of surgical removal (splenectomy or mass excision) rather than by fine-needle aspiration, as aspirating vascular tumors risks hemorrhage and may not yield diagnostic cells.

Step 7: Emerging Diagnostic Tools

• Liquid biopsy / cell-free DNA testing: Products such as the Nu.Q Canine Cancer Test and similar assays detect tumor-derived DNA or nucleosomes in blood, showing promise for early detection in at-risk breeds.
• CADET BRAF mutation test and other biomarker panels are under active investigation for canine HSA.

Treatment Options for Hemangiosarcoma

Treatment strategy depends on tumor location, extent of metastatic disease, and the owner's goals. Because HSA is typically diagnosed at an advanced stage, treatment is frequently palliative rather than curative—aimed at extending quality life.

Medical Management

• Doxorubicin-based protocols (e.g., doxorubicin alone or the VAC protocol — vincristine, doxorubicin, cyclophosphamide) are the most commonly used regimens.
• Metronomic chemotherapy (low-dose continuous oral drugs such as cyclophosphamide and chlorambucil combined with NSAIDs) is used in dogs that cannot tolerate or whose owners decline standard IV chemotherapy.
• Chemotherapy extends median survival from approximately 1–2 months post-surgery to 4–6 months in splenic HSA.

Surgical Options

• Splenectomy (surgical removal of the spleen) is the standard of care for splenic HSA. It stops active or impending hemorrhage and provides tissue for diagnosis. Without chemotherapy following surgery, median survival is 1–2 months due to pre-existing microscopic metastasis.
• Pericardectomy (removal of the pericardial sac) may be performed for cardiac HSA to relieve recurrent pericardial effusion and improve quality of life, though it is not curative.
• Excision of cutaneous/subcutaneous masses offers the best prognosis among HSA subtypes; dermal (skin surface) HSA has significantly longer survival times than visceral forms, particularly when wide surgical margins are achieved.

Alternative and Supportive Therapies

• Yunnan Baiyao: This traditional Chinese herbal supplement has demonstrated some evidence of reducing bleeding tendency in dogs with splenic masses and is widely used as a palliative adjunct. It is not a substitute for surgery or chemotherapy.
• Immunotherapy / I'm-Yunity mushroom extract (PSK): One small study suggested that a polysaccharide extract from Coriolus versicolor mushrooms extended survival in dogs with splenic HSA post-splenectomy without chemotherapy. Larger trials are ongoing.
• Anti-angiogenic agents and NSAIDs: Piroxicam and other NSAIDs may have mild anti-tumor and anti-angiogenic effects and are often incorporated into palliative protocols.
• Nutritional support: High-protein, low-simple-carbohydrate diets are generally recommended for cancer patients to counter cachexia.

At-Home Care

• Monitor gum color daily — white or pale gums are an emergency.
• Keep activity moderate; avoid intense exercise that could precipitate tumor rupture.
• Administer prescribed medications consistently and report any side effects promptly.
• Maintain scheduled recheck appointments (typically every 4–6 weeks during chemotherapy).
• Provide a calm, comfortable environment and maintain consistent routines.
• Work with your veterinary team to establish a clear quality-of-life framework and end-of-life plan.

Prognosis & Life Expectancy

Hemangiosarcoma carries a guarded to poor prognosis, and honesty about outcomes helps owners make informed decisions. Survival times vary significantly by tumor location:

| Location | Surgery Alone | Surgery + Chemotherapy | |---|---|---| | Splenic HSA | Median 1–2 months | Median 4–6 months | | Cardiac HSA | Median 1–4 months (pericardectomy) | Limited data; similar or slightly longer | | Dermal (skin surface) HSA | Median 12+ months | Often curative with wide excision | | Subcutaneous HSA | Median 6 months | Median 6–12 months | | Hepatic HSA | Median 1–2 months | Limited data |

Approximately 90% of dogs with internal HSA already have microscopic metastasis at the time of diagnosis, which is the primary reason long-term remission is uncommon. A small percentage (roughly 10%) of dogs treated with surgery and chemotherapy survive beyond one year.

Despite these statistics, many dogs maintain good quality of life during remission, and for owners, even several additional months of comfortable time with their pet can be deeply meaningful. Palliative care focused on comfort and quality of life is a fully valid and compassionate choice when curative intent treatment is not pursued.

---

Prevention

There is currently no guaranteed method to prevent hemangiosarcoma, but several strategies may reduce risk or improve the chances of early detection:

• Routine veterinary exams: Annual wellness exams (twice yearly for dogs over 7) with abdominal palpation can sometimes identify early splenic changes.
• Ultrasound screening: High-risk breeds such as Golden Retrievers and German Shepherds may benefit from annual or biannual abdominal ultrasound starting at age 6–7, allowing detection of splenic masses before rupture.
• Liquid biopsy testing: Emerging blood-based cancer screening tests for at-risk breeds are becoming more accessible and may allow earlier detection in the future.
• Sun protection: For light-coated dogs, limiting prolonged UV exposure to the sparsely haired ventral abdomen and applying dog-safe sunscreen may reduce the risk of dermal HSA.
• Responsible breeding: Breeders of high-risk breeds should track cancer histories in pedigrees. DNA-based genetic risk testing for cancer predisposition in Golden Retrievers and related breeds is an evolving field.
• Healthy lifestyle: Maintaining a healthy body weight, providing regular moderate exercise, and feeding a balanced diet support general immune health, though no specific diet has been proven to prevent HSA.

Cost of Treatment

The cost of managing hemangiosarcoma can be substantial. Below are general ranges:

| Service | Estimated Cost (USD) | |---|---| | Initial bloodwork (CBC, chemistry, coagulation) | $150–$400 | | Abdominal ultrasound | $300–$600 | | Chest X-rays | $150–$250 | | Echocardiogram | $400–$800 | | CT scan (staging) | $1,500–$2,500 | | Splenectomy (surgery) | $2,000–$5,000 | | Histopathology | $200–$400 | | Doxorubicin chemotherapy (5 cycles) | $2,000–$4,000 | | Metronomic oral chemotherapy (monthly) | $100–$300/month | | Emergency stabilization / blood transfusion | $1,500–$4,000 | | Total (surgery + chemotherapy) | $5,000–$12,000+ |

Costs vary widely by geographic region and facility type (general practice vs. specialty/emergency hospital). Pet insurance that covers hereditary conditions may offset costs significantly. Many veterinary oncology centers offer payment plans, and organizations such as the Veterinary Cancer Society can help connect owners with financial assistance resources.

---

Frequently Asked Questions

---

This article was written for educational purposes. It does not replace professional veterinary advice, diagnosis, or treatment. If you are concerned about your dog's health, please contact your veterinarian promptly.